Reply to Office Action mailed on January 31, 2012

IN THE CLAIMS:

This Listing of Claims below will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claim 1 (withdrawn): A method for identifying a pharmaceutical dosage form comprising:

detecting the presence of a scent or scent profile that has been imparted to the dosage form during manufacture of the dosage form, wherein the scent or scent profile in the dosage form is of a type and in an amount that is useful to identify the source of the dosage form; the detecting step is carried out utilizing a non-human animal or an electronic olfactory measuring device; and the dosage form is a tablet or a capsule, and

authenticating the dosage form,

wherein the detection of the scent or scent profile indicates that the dosage form is authentic.

Claim 2 (withdrawn): The method of claim 1, wherein the dosage form comprises an opioid analgesic.

Claim 3 (currently amended): A method for providing for the identification of a pharmaceutical dosage form comprising:

imparting a scent or scent profile to a pharmaceutical dosage form comprising an active agent during manufacture of the dosage form; which scent or scent profile in the dosage form is of a type and in an amount useful to determine the identity or source of the dosage form; which scent or scent profile is of a type and in an amount in the dosage form that is detectable by a non-human animal or an electronic olfactory measuring device; and

allowing for an authentication of the dosage form by associating the scent or scent profile with the identity of the dosage form.

wherein the dosage form is a tablet or a capsule,

the scent or scent profile indicates when and/or where the pharmaceutical dosage form was manufactured, bottled or packaged, and the presence of the scent or scent profile indicates that the dosage form is authentic.

Claim 4 (withdrawn): The method of claim 1, wherein the amount of the scent or scent profile in the dosage form is below the human olfactory threshold of the scent or scent profile.

Claim 5 (cancelled)

Claim 6 (currently amended): A method for providing for the identification of a pharmaceutical dosage form comprising:

selecting a pharmaceutical dosage form containing an active ingredient that has been approved by a governmental agency for distribution and sale to the public;

imparting a scent or scent profile useful to determine the identity or source of the dosage form to the dosage form during manufacture of the dosage form in an amount that does not require re-approval by the governmental agency of the dosage form reformulated to include the scent or scent profile; which scent or scent profile is of a type and in an amount in the dosage form that is detectable by a non-human animal or an electronic olfactory measuring device; and

allowing for an authentication of the dosage form by associating the scent or scent profile with the identity or source of the dosage form;

wherein the dosage form is a tablet or a capsule, and the presence of the scent or scent profile indicates that the dosage form is authentic.

Claims 7-10 (cancelled)

Claim 11 (withdrawn): A method of determining whether a pharmaceutical dosage form is a counterfeit product, comprising:

authenticating the pharmaceutical dosage form by testing a pharmaceutical dosage form of unknown identity or unknown source for the presence of a scent or scent profile that is the same as that of an authentic version of the pharmaceutical dosage form, wherein the tested dosage form is a tablet or a capsule, and the absence of the scent or scent profile, or the failure to match the scent profile, indicates that the tested dosage form of unknown identity or unknown source is a counterfeit product.

Appl. No. 10/698,981 Response dated July 27, 2012

Reply to Office Action mailed on January 31, 2012

Claims 12-73 (cancelled)

Claim 74 (previously presented): The method of claim 3, wherein the amount of the scent or

scent profile in the dosage form is below the human olfactory threshold of the scent or scent

profile.

Claim 75 (previously presented): The method of claim 3, wherein the scent or scent profile is

detectably varied between different batches of the dosage form so as to enable the ability to

distinguish between the different batches of the dosage form using a non-human animal or an

electronic olfactory measuring device.

Claim 76 (previously presented): The method of claim 3, wherein the dosage form comprises an

opioid analgesic.

Claim 77 (previously presented): The method of claim 6, wherein the amount of the scent or

scent profile imparted to the dosage form is below the human olfactory threshold of the scent or

scent profile.

Claim 78 (previously presented): The method of claim 6, wherein the scent or scent profile is

detectably varied between different batches of the dosage form so as to permit distinguishing

between the different batches of the dosage form using a non-human animal or an electronic

olfactory measuring device.

Claim 79 (previously presented): The method of claim 6, wherein the dosage form comprises an

opioid analgesic.

Claim 80 (currently amended): A method for providing for the identification of a pharmaceutical

dosage form comprising:

allowing for an authentication of the dosage form by imparting a scent or scent profile

useful to determine the identity or source of the dosage form to a pharmaceutical dosage form

4

comprising an active agent during manufacture of the dosage form, which scent or scent profile is in an amount or concentration which (i) is below the human olfactory threshold of the scent or scent profile and (ii) is detectable by a non-human animal or an electronic olfactory measuring device.

wherein the dosage form is a tablet or a capsule, and the presence of the scent or scent profile indicates that the dosage form is authentic.

Claim 81 (withdrawn): The method of claim 80, wherein the electronic olfactory measuring device is a handheld electronic olfactory measuring device.

Claim 82 (previously presented): The method of claim 80, further comprising the step of associating the scent or scent profile with the identity or source of the dosage form.

Claim 83 (withdrawn): The method of claim 82, wherein the association of the scent or scent profile with the identity or source of the dosage form is by a software program installed in the electronic olfactory measuring device.

Claim 84 (previously presented): A method for providing for the identification of a pharmaceutical dosage form, comprising:

imparting a scent or scent profile useful to determine the identity or source of the dosage form to a pharmaceutical dosage form comprising an active agent during manufacture of the dosage form, which scent or scent profile is in an amount or concentration which is detectable by a non-human animal or an electronic olfactory measuring device, and

allowing for an authentication of the dosage form by associating the scent or scent profile with the source of the dosage form,

wherein the dosage form is a tablet or a capsule, and the presence of the scent or scent profile indicates that the dosage form is authentic.

Claim 85 (withdrawn): The method of claim 84, wherein the electronic olfactory measuring device is a handheld electronic olfactory measuring device.

Claim 86 (previously presented): The method of claim 84, wherein the amount of the scent or scent profile imparted to the dosage form is below the human olfactory threshold of the scent or scent profile.

Claim 87 (withdrawn): The method of claim 84, wherein the scent or scent profile is detectably varied between different batches of the dosage form so as to permit distinguishing between the different batches of the dosage form using a non-human animal or an electronic olfactory measuring device.

Claim 88 (previously presented): The method of claim 84, wherein the dosage form comprises an opioid analgesic.

Claim 89 (withdrawn): A method for identifying a pharmaceutical dosage form comprising:

detecting the presence of a scent or scent profile that has been imparted to the dosage
form during manufacture of the dosage form, wherein the scent or scent profile imparted to the
dosage form is of a type and in an amount that is useful to identify the source of the dosage form;
and wherein the detecting step is carried out utilizing means for said detection, and
authenticating the dosage form.

wherein the dosage form is a tablet or a capsule, and the detection of the scent or scent profile indicates that the dosage form is authentic.

Claim 90 (previously presented): The method of claim 80, wherein the dosage form comprises an opioid analgesic.

Claim 91 (previously presented): The method of claim 3, wherein the scent or scent profile being imparted is not already associated with the dosage form.

Claim 92 (previously presented): The method of claim 6, wherein the scent or scent profile being imparted is not already associated with the dosage form.

Appl. No. 10/698,981 Response dated July 27, 2012 Reply to Office Action mailed on January 31, 2012

Claim 93 (previously presented): The method of claim 80, wherein the scent or scent profile being imparted is not already associated with the dosage form.

Claim 94 (previously presented): The method of claim 84, wherein the scent or scent profile being imparted is not already associated with the dosage form.

Claim 95 (previously presented): The method of any one of claims 1-4, 6, 11, or 74-94, wherein the tablet is a sustained release tablet.

Claim 96 (Cancelled)

Claim 97 (previously presented): The method of claim 95, wherein the scent is in a coating of the dosage form.

Claim 98 (previously presented): The method of any one of claims 1-4, 6, 11, or 74-94, wherein the scent is in a sequestered form.

Claim 99 (previously presented): The method of claim 3, wherein the dosage form has been approved by a governmental agency for distribution and sale to the public.

Claim 100 (previously presented): The method of claim 1, wherein the dosage form has been approved by a governmental agency for distribution and sale to the public.

Claim 101 (previously presented): The method of claim 80, wherein the dosage form has been approved by a governmental agency for distribution and sale to the public.

Claim 102 (previously presented): The method of claim 84, wherein the dosage form has been approved by a governmental agency for distribution and sale to the public.

Claim 103 (previously presented): The method of claim 3, wherein the dosage form is free from perfluorocarbon tracers.

Claim 104 (previously presented): The method of claim 3, wherein the scent or scent profile allows for determination of manufacturing date or a batch number of the dosage form.

Claim 105 (previously presented): The method of claim 6, wherein the scent or scent profile allows for determination of manufacturing date or a batch number of the dosage form.

Claim 106 (previously presented): The method of claim 80, wherein the scent or scent profile allows for determination of manufacturing date or a batch number of the dosage form.

Claim 107 (previously presented): The method of claim 80, wherein the scent or scent profile allows for determination of manufacturing date or a batch number of the dosage form.